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The aim of the study was to determine whether modulation of 5-fluorouracil (FU) by methotrexate (MTX) improves survival
compared to FUþ6-s-leucovorin (LV) following potentially curative resection of stage II and III colon cancer. Within 8 weeks from
surgery, 1945 patients with stage III (44%) or high-risk stage II (55%) colon cancer were randomly assigned to receive either 6
monthly cycles of FU 370mgm
 2 i.v. bolus preceded by LV 100mgm
 2 i.v. bolus on days 1–5, or 6 monthly cycles of sequential
MTX 200mgm
 2 i.v. days 1 and 15 and FU 600mgm
 2 i.v. on days 2 and 16 followed by LV rescue (15mg given p.o. q 6h 6
doses). Levamisole 50mg p.o. t.i.d. on days 1–3, every 14 days for 6 months, was planned to be given in both arms. After a median
follow-up of 4.2 years, 568 patients have relapsed and 403 have died. Survival was similar with MTX-FU and FUþLV (77 vs 77% at
5 years; P¼0.90), as were 5-year disease-free survivals (67 vs 63%; P¼0.44). Efficacy results were similar for both stage III and II
patients. There were two toxic deaths, two in the MTX-FU arm (0.2%) and zero in the control arm. We conclude that biochemical
modulation of FU with LV or with MTX produces similar results in the adjuvant setting of colon cancer.
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A series of improvements have been made in the adjuvant
treatment of node-positive colon cancer. The first was the
demonstrated efficacy of 12 months of 5-fluorouracil (FU)
levamisole in 1990 (Moertel et al, 1990) and of FU 6-s-leucovorin
(LV) in 1993 (Wolmark et al, 1993), and the second was the proven
equivalence of only 6 months of FU LV to the standard 12 months
of FU levamisole, 5 years later (Haller et al, 1998). The third was
the demonstration that the benefit of adjuvant chemotherapy
extends to elderly patients as well (Sargent et al, 2001). And the last
advancement regards the additional substantial benefit that the
doublet FUþoxaliplatin provides as compared to optimal FU
chemotherapy (Andre et al, 2004). Other issues have been
addressed and definitely answered by large-scale randomised
trials in the last 5 years. Such is the case for the optimal dose of LV
to potentiate FU: no need for high dose (Haller et al, 1998; Quasar,
2000); the best schedule of FU LV: equivalence between the weekly
and the monthly schedule (Kerr, 2000), the lack of efficacy of
levamisole (Haller et al, 1998; Quasar, 2000), the equivalence of the
bolus and infusional FU regimens (Andre et al, 2003) and the
inefficacy of short-term early postoperative intraportal FU
infusions (Liver infusion meta-analysis group, 1997).
INTACC is an Italian intergroup that has recently reported
another large-scale randomised trial of adjuvant chemotherapy for
colon cancer comparing FU levamisole vs FU LV levamisole (Di
Costanzo et al, 2003). When the accrual of that first study was
completed in February 1995, levamisole was still considered part of
the standard adjuvant treatment. We postulated that our experi-
mental arm in the first study was unlikely to be inferior to the
standard arm and used that arm, FU LV levamisole, given for 6
months as control of the second study. The experimental arm was
decided to be the sequential combination of methotrexate
(MTX)-FU (Marsh et al, 1991) along with levamisole. This
choice was based on the results of the meta-analysis on MTX-FU
vs FU in the advanced setting (Advanced colorectal cancer
metaanalysis, 1994), suggesting that it was reasonable to test this
combination in the adjuvant setting. The design of this trial seems
definitely outdated in 2004, but at the time of planning, only an
alternative modulation of FU other than LV could be feasible
within our intergroup.
To our knowledge, this is the first reported study of adjuvant
MTX-FU and we are unaware of any other such study on-
going. As we will discuss, some of the findings of this study may
have important implications for the design of future adjuvant
studies.
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Eligibility criteria
All patients were required to have had a histological proof of colon
carcinoma above the peritoneal reflection, complete resection of
the primary tumour without gross or microscopic evidence of
residual disease, regional lymph node involvement and or
transmural penetration of the muscular wall of the bowel with or
without adherence or penetration into an adjacent organ (Dukes’
stages B2, B3 and C according to Modified Astler and Coller, 1987
classification). A minimum number of lymph nodes was not
required by the protocol for defining a patient as node negative.
(AJCC, 1987) ECOG performance status p1, age X18 years,
normal hepatic and renal function and informed consent were also
required.
The colon tumour was defined as any lesion of the large bowel
which did not require the opening of the pelvic peritoneum to
define the distal extent of the tumour and/or 412cm from
pectinate line but with the inferior margin of the tumour above the
peritoneal reflection.
Patients were ineligible if they were pregnant or lactating, had
had prior or concurrent radiation or chemotherapy for colon
cancer, had had previous or concurrent second malignant disease
(except superficial squamous or basal-cell skin carcinoma of the
skin or in situ carcinoma of the cervix) or nonmalignant systemic
disease precluding administration of chemotherapy. Those with
WBC count less than 3500ml
 1 and platelet count less than
100000mL
 1, were ineligible.
Patients were accrued from five central and northern Italian
cooperative groups for a total of 71 centres: Gruppo Oncologico
Italiano di Ricerca Clinica (GOIRC), Gruppo Cooperativo Istituto
Nazionale per la Ricerca sul Cancro (Ist-Genova), Gruppo
Oncologico del Nord-Ovest (GONO), Gruppo Oncologico Piemon-
tese Tumori Apparato Digerente (GOPTAD) and Istituto Oncolo-
gico Romagnolo (IOR).
Treatment
After stratification for centre, patients were randomly assigned to
receive either 6 monthly cycles of FU 370mgm
 2 i.v. bolus
preceded by LV 100mgm
 2 i.v. bolus on days 1–5 or 6 monthly
cycles of sequential MTX 200mgm
 2 i.v. days 1 and 15 and FU
600mgm
 2 i.v. on days 2 and 16 followed by LV rescue (15mg
given p.o. q 6h 6 doses). No serum MTX level measurements
were required on a routine basis. Levamisole 50mg p.o. t.i.d. on
days 1–3, every 14 days for 6 months. was given in both arms. The
treatment was started within 60 days from surgery.
Toxicity was defined according to the World Health Organisa-
tion (WHO) criteria. Treatment was repeated at full doses if WBC
was 43500ml and PLT 4100000ml; chemotherapy dose was
delayed if WBC was o3500ml and/or PLT o100000ml at recycle.
Chemotherapy was stopped for any grade (gr) 4 toxicity. FU was
repeated at full dose in case of gr 1 diarrhoea or mucositis, whereas
the dose was reduced by 25% for gr 2–3. Dose reduction of MTX,
LV and levamisole were not allowed, since all these agents were
used as modulators of FU. Investigators were required to notify the
trial office by telephone of any serious unexpected adverse event.
Follow-up
Forms were sent to the Data Centre of the study for each patient
upon study entry and every 6 months for the first 3 years and
yearly thereafter. Before each course of therapy, patients had to
undergo a physical examination, haematologic and renal function
studies and serum carcinoembryonic antigen. After completion of
therapy, these tests were repeated every 6 months for the first 2
years and then every year for a total of 5 years.
During follow-up, colonoscopy or barium enema were recom-
mended every 2 to 3 years. Chest X-ray and hepatic ultrasound or
CT scan were performed every 6 months for the first 2 years, then
every year until the 5th year. The treatment of relapse was not
standardised and was left up to the investigators.
Study end points and statistical methods
The main end point of the study was overall survival (OS); the
secondary end point was DFS. A minimum sample size of 1500
patients (with annual accrual of 500 for 3 years) was set to ensure
an 80% probability of detecting a 20% relative reduction in overall
mortality after 5 years of follow-up, assuming a constant hazard
rate equal to 8% per year (11) in the control arm, leading to an
expected OS of 67% at 5 years.
Randomisation was centralised at the coordinating centres of
Genova (for Genova, GONO and GOPTAD), GOIRC and IOR.
Randomisation lists were generated with blocks of variable length
in random sequence, unknown to clinicians. The clinical centre
was the only stratification factor. All the analyses were carried out
according to the intention-to-treat principle in that all randomised
patients were included in the analyses. Overall survival was
computed as the time from randomisation to death due to any
cause. Disease-free survival (DFS) was computed as the time from
randomisation to the first observation of disease relapse or
occurrence of a second primary cancer, or death due to any cause.
Kaplan–Meier estimate and log-rank test allowed comparisons
among the curves. Overall survival and DFS analyses performed
according to the treatment were stratified according to disease
stage (TNM stage II and III). Cox’s regression analysis was used to
model OS and DFS as a function of a set of independent variables.
All the variables were categorical: treatment assigned at randomi-
sation (standard, experimental); ECOG performance status (0, 1);
histological grading (1¼well, 2¼moderately wellþmissing va-
lues, 3¼poorly differentiated; patients with missing values of
grading were considered as G2 patients); TNM stage of disease
(stage II, stage III with one to four positive nodes, stage III with
X5 positive nodes); gender; and site of disease (1¼right colon:
caecum, ascending colon and hepatic flexure; 2¼left colon:
transverse colon, splenic flexure and descending colon;
3¼intraperitoneal rectum and sigmoid; 4¼multiple locations).
Age was used as a stratification factor. For Cox’s regression
analysis, a backward procedure was used with P in¼0.05 and P
out¼0.10. All P-values were two-sided. SPSS 11.0 statistical
package was used for all the analyses.
RESULTS
Between March 1995 and February 1998, 1945 patients were
accrued from 71 Italian centres (Consort diagram, Figure 1) and
their characteristics are shown in Table 1. The median number of
patients per centre was 19, but more than 50% of the patients were
accrued from 14 centres. In terms of age group distribution, 17.0%
were older than 70 years and 2.8% younger than 40 years. Among
the protocol violations, eight patients had unknown PS, 19 patients
were randomised after 60 days from surgery and 73 patients
started chemotherapy longer than 8 weeks from surgery. In
addition, 23 patients were ineligible for staging problems
(five patients were stage I, one stage IV and 17 had no mention
of the stage). About 55% patients were stage II and they were
equally distributed in the two arms, which were well balanced in
terms of the other major patients characteristics; among stage II
and III, 91 had no information regarding lymph node status. In
most of these cases, 74 of 91, the pathology report stated either
‘Dukes’ C’ or ‘Dukes’ B 2–3’, while 17 had missing stage
information.
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pathology report (N¼1854 surgical operations) was 12 for stage II
(range 0–74) and 12 for stage III patients (range 0–70).
The median time from surgery to randomisation and to the
beginning of chemotherapy were 31 and 39 days, respectively.
Compliance to treatment and toxicity
In all, 72% of the patients completed the planned six cycles of
MTX-FU and 77% completed FU LV; approximately 12%
discontinued the treatment after completing only three cycles (3
months) of therapy and 2% never started chemotherapy in either
arm. No patients received more than the planned six cycles.
Levamisole was never started in 22.2% of the experimental arm
and in 21.7% of the control arm, and it was discontinued for
toxicity, refusal or other reasons in another 20%, so that only 60%
of patients received the immunomodulator according to the
protocol. This was not an unexpected finding as this trial accrued
patients when levamisole’s efficacy was beginning to be challenged.
There were two toxic deaths in the MTX-FU and none in the
control arm. One patient died of diarrhoea, dehydration and sepsis
after the first cycle and the other of severe mucositis, diarrhoea
and dehydration with shock. Overall, the two treatments had
similar degrees of toxicity, although slightly different patterns
(Table 2). Thrombocytopenia was more pronounced in the MTX-
FU arm (2.2 vs 0.1%, gr 3 and 4). The same was true for mucositis
(14.8 vs 11.7%), while the reverse occurred for diarrhoea (6.5 vs
12.6%, gr 3 and 4). Conjunctivitis of low grade (1 and 2) was twice
more frequent in the experimental arm (21.2 vs 12.6%). Hand and
foot syndrome of low grade occurred in 5% of FU LV- and in 2.8%
of MTX-FU-treated patients (P¼0.02). Neurotoxicity and hepa-
totoxicity was reported in fewer than 1% of cases in either arm.
Efficacy
After a median follow-up time of 4.2 years, 198 (20.6%) deaths
were observed in the experimental arm and 205 (20.5%) in the
control arm; recurrences were 269 (28.0%) and 299 (30.3%) in the
experimental and in the control arm, respectively. Univariate and
multivariate hazard ratios are 0.94 (0.8–1.12) and 0.93 (0.78–1.1)
for relapse, and 1.01 (0.83–1.23) and 1.03 (0.84–1.26) for overall
mortality.
The sites of initial recurrence were not significantly different
between arms; in patients treated with MTX-FU, they were the
liver in 23.2%, other sites within the abdominal cavity in 20.2%,
the lungs in 6.8% and multiple in 19.8%, while second primary
tumours were reported in 5.7% of cases. Corresponding figures for
the control arm were, respectively, 27.7, 17.9, 4.9, 21.4 and 5.3%.
Aside from the two toxic deaths described, 37 deaths (10.4%) were
unrelated to cancer, 22 (12.7%) in the experimental arm and 15
(8.2%) in the control arm.
Figures 1 and 2 show that survival was similar with MTX-FU
and FUþLV (77 vs 77% at 5 years; P¼0.90), as were DFSs (67 vs
63% at 5 years; P¼0.44). Efficacy results were similar for both
stage III and II patients (Figure 3).
The hazard ratio for recurrence and death adjusted for stage
were 0.99 (95% confidence limits¼0.82–1.21) and 1.07 (95%
confidence limits¼0.96–1.19), respectively.
DISCUSSION
At the time the study was designed, irinotecan and oxaliplatin were
not available even for experimental use in the adjuvant setting and
it was thought that comparing the sequential MTX-FU combina-
tion to standard FU LV (maintaining levamisole in both arms) was
reasonable and appealing for a large-scale pragmatic trial for three
reasons. First, while the meta-analysis on FU LV vs FU failed to
show a significant survival benefit (Advanced colorectal cancer
metaanalysis, 1992), the meta-analysis on MTX-FU did so,
although the difference was small (Advanced colorectal cancer
metaanalysis, 1994). Second, the meta-analysis on MTX-FU
included several trials designed without the demonstrated optimal
interval between the antifol and the fluoropyrimidine (4–24h)
Randomised
n =1945
Allocated to 5-FU + Leva + LV arm       n = 985
Received allocated treatment               n = 965
Did not received allocated treatment    n = 20
Allocated to 5-FU + Leva + MTX arm   n = 960
Received allocated treatment               n = 941
Did not received allocated treatment    n = 19
Discontinued treatment  n = 207 Discontinued treatment  n = 250
Analysed        n = 985
Excluded from analysis n = 0
Analysed        n = 960
Excluded from analysis n = 0
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Figure 1 Consort diagram of the study.
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appropriate scheduling, as we chose for our study. Third, while LV
modulates FU by enhancing its anti-DNA effects via the inhibition
of thymidylate synthase, MTX modulates FU primarily by
increasing the incorporation of fluorouracil triphosphate into
RNA, adding pharmacodynamic interest to the comparison
(Sobrero et al, 1997). In 1995, all these good reasons appeared to
justify this adjuvant trial.
Despite a certain percentage of missing data regarding patient
and tumour characteristics, understandable in a large pragmatic
trial, the overall good quality of colon cancer care in this trial is
proven by two indirect indicators: the median number of lymph
nodes removed at surgery, 12, and the very good 3-year DFS value,
74%. This value matches well with that of the control arm of the
MOSAIC (Andre et al, 2004) study (73%), which in turn was
identical to another European large study of adjuvant chemother-
apy in this disease (Andre et al, 2003).
The large sample size of the study and the similarity of the OS
and DFS curves in the two arms fail to demonstrate clinically
relevant differences in efficacy between the regimens. Since the
toxicity and duration of the two treatments are also similar,
MTX-FU may be considered an alternative to FUþLV, but offers
no advantage, even from the convenience standpoint.
The equivalence observed allows to speculate on the relevance of
the total dose of FU in the adjuvant treatment of this disease. The
classic FU levamisole used a total of 27gm
 2, the weekly NSABP
regimen employed 18gm
 2 and in a later version 12gm
 2 and the
monthly cycle between 11.1gm
 2 (as in the control arm of our
trial) and 12.75gm
 2. Our MTX-FU regimen used only 7.2gm
 2.
Despite its low activity as single agent against advanced disease,
it is possible that MTX contributes as a cytotoxic to the efficacy
of FU or that it is a better modulator than LV (as it was
our hypothesis), thus accounting for the overall efficacy of so little
FU. However, it is also likely that very little FU is needed
for efficacy in sensitive patients. And these speculations may be
Table 1 Patient characteristics by treatment arm
5-FU+levamisole+MTX (960 pts) 5-FU+levamisole+LV (985 pts) All patients (1945)
Median age (years) (range) 62 (30–83) 63 (25–80) 62 (25–83)
Gender (%)
Male 560 (58.3) 575 (58.4) 1135 (58.4)
Female 400 (41.7) 410 (41.6) 810 (41.6)
ECOG performance status (%)
0 858 (89.8) 888 (90.4) 1746 (90.1)
1 97 (10.2) 94 (9.6) 191 (9.9)
Unknown 5 3 8
Stage (%)
Dukes B 517 (54.8) 543 (55.5) 1060 (55.2)
Dukes C 423 (45.2) 433 (44.3) 856 (44.8)
Other 14 9 23
Tumour location (%)
Right colon 256 (27.4) 311 (32.5) 567 (30.0)
Left colon 667 (71.5) 631 (65.8) 1298 (68.6)
Multiple locations 10 (1.1) 16 (1.7) 26 (1.4)
Unknown 27 27 54
Surgery (%)
Right hemicolectomy 289 (31.0) 336 (35.1) 625 (33.1)
Left hemicolectomy 298 (31.9) 292 (30.5) 590 (31.2)
Resection of sigmoid 169 (18.1) 174 (18.1) 343 (18.1)
Anterior resection 91 (9.8) 80 (8.4) 171 (9.0)
Other 86 (9.2) 76 (7.9) 162 (8.6)
Unknown 27 27 54
Histology (%)
Adenocarcinoma 918 (99.6) 951 (99.7) 1869 (99.6)
Undifferentiated 4 (0.4) 3 (0.3) 7 (0.4)
Unknown 38 31 69
Grade of anaplasia (%)
G1 84 (9.6) 70 (7.9) 154 (8.7)
G2 657 (75.2) 675 (75.9) 1332 (75.6)
G3 133 (15.2) 144 (16.2) 277 (15.7)
Unknown 86 96 182
5-FU¼5-fluorouracil; MTX¼methotrexate; ECOG¼Eastern Cooperative Oncology Group.
Table 2 Grade 3–4 toxicity (%)
5-FU+levamisole
+MTX
(960 pts)
5-FU+levamisole+LV
(985 pts) P-value
Leukopenia 35(4) 25(2.7) 0.16
Thrombocytopenia 19(2.2) 1(0.1) o0.0001
Anaemia 8(0.9) 4(0.4) 0.39
Mucositis 131(14.8) 107(11.7) 0.048
Diarrhoea 57(6.5) 115(12.6) o0.0001
Nausea and vomiting 31(3.5) 21(2.3) 0.12
Conjunctivitis 6(0.7) 2(0.2) 0.13
Hand–foot syndrome 2(0.2) 7(0.8) 0.12
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new, most efficacious FUþoxaliplatin combination cannot be
tolerated by a large proportion of patients because of cumulative
neurotoxicity.
Along the line of speculation, if only very little FU is sufficient,
these data may provide additional rationale to identify the
sensitive patient population. The recent work on TS, DCC, LOH
18q and MSI (Jen et al, 1994; Lenz et al, 1998; Halling et al, 1999;
Gryfe et al, 2000; Watanabe et al, 2001) are good examples of such
strategies. For FU-sensitive patients, very few courses of FU
adjuvant chemotherapy may be sufficient, for the others, repeated
cycles of FU administrations are likely to be entirely ineffective and
FU might well be omitted from the adjuvant treatment programme
in these patients.
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